Digital Aria Co Ltd (115450) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.006x

Based on the latest financial reports, Digital Aria Co Ltd (115450) has a cash flow conversion efficiency ratio of 0.006x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.10 Billion ≈ $744.49K USD) by net assets (₩173.86 Billion ≈ $117.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Digital Aria Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Digital Aria Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Digital Aria Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Digital Aria Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Digital Aria Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
VietinBank Securities JSC
VN:CTS
0.060x
Shanghai Jinqiao Export Processing Zone Development Co Ltd B
SHG:900911
-0.111x
Selan Exploration Technology Limited
NSE:SELAN
0.214x
Chicago Atlantic BDC, Inc.
NASDAQ:LIEN
0.000x
SHANGH.DAZ.PUBL.UTIL.YC 1
F:6WL
N/A
Heron Therapeuti
NASDAQ:HRTX
0.089x
Sierra Madre Gold and Silver Ltd
V:SM
-0.004x
Hathway Cable & Datacom Limited
NSE:HATHWAY
0.027x

Annual Cash Flow Conversion Efficiency for Digital Aria Co Ltd (2011–2025)

The table below shows the annual cash flow conversion efficiency of Digital Aria Co Ltd from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Digital Aria Co Ltd (115450) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ₩173.86 Billion
≈ $117.82 Million
₩-8.18 Billion
≈ $-5.54 Million
-0.047x -675.17%
2024-12-31 ₩157.46 Billion
≈ $106.71 Million
₩1.29 Billion
≈ $872.70K
0.008x -57.84%
2023-12-31 ₩171.52 Billion
≈ $116.24 Million
₩3.33 Billion
≈ $2.25 Million
0.019x +125.70%
2022-12-31 ₩116.71 Billion
≈ $79.09 Million
₩-8.81 Billion
≈ $-5.97 Million
-0.075x +20.51%
2021-12-31 ₩118.68 Billion
≈ $80.43 Million
₩-11.27 Billion
≈ $-7.64 Million
-0.095x +27.18%
2020-12-31 ₩89.35 Billion
≈ $60.55 Million
₩-11.65 Billion
≈ $-7.90 Million
-0.130x -50.39%
2019-12-31 ₩63.94 Billion
≈ $43.33 Million
₩-5.54 Billion
≈ $-3.76 Million
-0.087x -68.84%
2018-12-31 ₩68.66 Billion
≈ $46.53 Million
₩-3.53 Billion
≈ $-2.39 Million
-0.051x +57.63%
2017-12-31 ₩38.44 Billion
≈ $26.05 Million
₩-4.66 Billion
≈ $-3.16 Million
-0.121x -51.17%
2016-12-31 ₩33.88 Billion
≈ $22.96 Million
₩-2.72 Billion
≈ $-1.84 Million
-0.080x +43.87%
2015-12-31 ₩30.08 Billion
≈ $20.39 Million
₩-4.30 Billion
≈ $-2.91 Million
-0.143x +39.24%
2014-12-31 ₩22.52 Billion
≈ $15.26 Million
₩-5.29 Billion
≈ $-3.59 Million
-0.235x -327.84%
2011-12-31 ₩18.38 Billion
≈ $12.46 Million
₩1.90 Billion
≈ $1.29 Million
0.103x --

About Digital Aria Co Ltd

KQ:115450 Korea Biotechnology
Market Cap
$210.89 Million
₩311.19 Billion KRW
Market Cap Rank
#16334 Global
#675 in Korea
Share Price
₩3530.00
Change (1 day)
+1.29%
52-Week Range
₩2545.00 - ₩9560.00
All Time High
₩25764.90
About

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrica… Read more